2709 related items for PubMed ID: 18640466
1. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
3. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
4. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
[Abstract] [Full Text] [Related]
5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 22; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
6. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
7. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
Clin Ther; 2007 Jun 10; 29(6):1128-45. PubMed ID: 17692727
[Abstract] [Full Text] [Related]
8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
Clin Ther; 2006 Feb 10; 28(2):266-79. PubMed ID: 16678648
[Abstract] [Full Text] [Related]
9. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 10; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
10. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
Mult Scler; 2009 Oct 10; 15(10):1195-205. PubMed ID: 19797261
[Abstract] [Full Text] [Related]
11. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
Acta Neurol Scand; 2006 Apr 10; 113(4):241-7. PubMed ID: 16542163
[Abstract] [Full Text] [Related]
12. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
[Abstract] [Full Text] [Related]
13. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, Hansen T, Danish Multiple Sclerosis Group.
Neurology; 2006 Apr 11; 66(7):1056-60. PubMed ID: 16510769
[Abstract] [Full Text] [Related]
14. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE.
Clin Ther; 2009 Oct 11; 31(10):2072-85. PubMed ID: 19922878
[Abstract] [Full Text] [Related]
15. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 11; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
16. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
Mult Scler; 2010 Jan 11; 16(1):68-77. PubMed ID: 19995846
[Abstract] [Full Text] [Related]
17. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
Temple AR, Benson GD, Zinsenheim JR, Schweinle JE.
Clin Ther; 2006 Feb 11; 28(2):222-35. PubMed ID: 16678643
[Abstract] [Full Text] [Related]
18. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
[Abstract] [Full Text] [Related]
19. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
Clin Ther; 2010 Jun 09; 32(6):1061-6. PubMed ID: 20637960
[Abstract] [Full Text] [Related]
20. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ.
Curr Med Res Opin; 2004 Jan 09; 20(1):25-30. PubMed ID: 14741068
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
